BioVie (BIVI) Competitors $2.15 +0.09 (+4.37%) (As of 05:19 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BIVI vs. IFRX, BMEA, ALGS, NBTX, XBIT, TELO, TIL, PBYI, VXRT, and ENTAShould you be buying BioVie stock or one of its competitors? The main competitors of BioVie include InflaRx (IFRX), Biomea Fusion (BMEA), Aligos Therapeutics (ALGS), Nanobiotix (NBTX), XBiotech (XBIT), Telomir Pharmaceuticals (TELO), Instil Bio (TIL), Puma Biotechnology (PBYI), Vaxart (VXRT), and Enanta Pharmaceuticals (ENTA). These companies are all part of the "pharmaceutical products" industry. BioVie vs. InflaRx Biomea Fusion Aligos Therapeutics Nanobiotix XBiotech Telomir Pharmaceuticals Instil Bio Puma Biotechnology Vaxart Enanta Pharmaceuticals BioVie (NASDAQ:BIVI) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends, community ranking and institutional ownership. Does the media refer more to BIVI or IFRX? In the previous week, InflaRx had 6 more articles in the media than BioVie. MarketBeat recorded 6 mentions for InflaRx and 0 mentions for BioVie. InflaRx's average media sentiment score of 0.50 beat BioVie's score of 0.00 indicating that InflaRx is being referred to more favorably in the news media. Company Overall Sentiment BioVie Neutral InflaRx Neutral Does the MarketBeat Community believe in BIVI or IFRX? InflaRx received 221 more outperform votes than BioVie when rated by MarketBeat users. However, 65.38% of users gave BioVie an outperform vote while only 64.67% of users gave InflaRx an outperform vote. CompanyUnderperformOutperformBioVieOutperform Votes1765.38% Underperform Votes934.62% InflaRxOutperform Votes23864.67% Underperform Votes13035.33% Which has more risk and volatility, BIVI or IFRX? BioVie has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Comparatively, InflaRx has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500. Which has preferable valuation and earnings, BIVI or IFRX? BioVie has higher earnings, but lower revenue than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioVieN/AN/A-$32.12M-$11.50-0.18InflaRx$168.50K898.11-$46.18M-$1.08-2.38 Do analysts prefer BIVI or IFRX? BioVie presently has a consensus price target of $3.00, indicating a potential upside of 47.06%. InflaRx has a consensus price target of $8.00, indicating a potential upside of 211.28%. Given InflaRx's higher probable upside, analysts plainly believe InflaRx is more favorable than BioVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00InflaRx 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is BIVI or IFRX more profitable? BioVie has a net margin of 0.00% compared to InflaRx's net margin of -33,362.70%. InflaRx's return on equity of -65.98% beat BioVie's return on equity.Company Net Margins Return on Equity Return on Assets BioVieN/A -182.62% -102.55% InflaRx -33,362.70%-65.98%-56.86% Do institutionals & insiders have more ownership in BIVI or IFRX? 4.6% of BioVie shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 4.0% of BioVie shares are held by insiders. Comparatively, 16.3% of InflaRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryInflaRx beats BioVie on 11 of the 15 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get BioVie News Delivered to You Automatically Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIVI vs. The Competition Export to ExcelMetricBioViePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.25M$6.66B$5.18B$9.21BDividend YieldN/A3.00%5.12%4.30%P/E Ratio-0.1810.5787.6517.17Price / SalesN/A192.331,165.15121.16Price / CashN/A57.1643.2337.84Price / Book0.805.104.794.79Net Income-$32.12M$151.58M$120.46M$225.43M7 Day Performance-18.07%-1.95%-0.97%-0.12%1 Month Performance-33.11%-4.27%15.25%1.56%1 Year Performance63.20%8.63%29.71%16.07% BioVie Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIVIBioVie1.1904 of 5 stars$2.15+4.4%$3.00+39.5%+64.8%$38.20MN/A-0.1910IFRXInflaRx2.4532 of 5 stars$2.51+12.1%$8.00+218.7%+46.2%$147.80M$168,498.00-2.3260News CoverageGap UpBMEABiomea Fusion3.9264 of 5 stars$4.05-4.3%$39.36+871.9%-71.8%$146.77MN/A-1.0150ALGSAligos Therapeutics4.2093 of 5 stars$39.65-0.5%$75.00+89.2%+122.0%$142.26M$6.00M-2.9890Gap UpHigh Trading VolumeNBTXNanobiotix2.1289 of 5 stars$3.01-2.9%$12.00+298.7%-54.8%$141.87M$36.22M0.00100Gap UpXBITXBiotech0.8442 of 5 stars$4.65-27.1%N/A+14.8%$141.75M$4.01M-4.31100News CoverageGap DownHigh Trading VolumeTELOTelomir PharmaceuticalsN/A$4.70-9.3%N/AN/A$139.17MN/A0.001News CoverageTILInstil Bio3.5363 of 5 stars$21.30+3.3%$145.00+580.8%+205.9%$139.00MN/A-1.8449News CoveragePositive NewsPBYIPuma Biotechnology3.97 of 5 stars$2.80+1.8%$7.00+150.0%-31.8%$137.45M$243.57M5.83185Analyst ForecastNews CoveragePositive NewsVXRTVaxart2.2128 of 5 stars$0.60-3.1%$3.00+399.6%+2.6%$136.60M$20.14M-1.46109ENTAEnanta Pharmaceuticals4.2211 of 5 stars$6.37+1.4%$19.50+206.1%-30.4%$135.01M$67.64M-1.16145Analyst Forecast Related Companies and Tools Related Companies InflaRx Competitors Biomea Fusion Competitors Aligos Therapeutics Competitors Nanobiotix Competitors XBiotech Competitors Telomir Pharmaceuticals Competitors Instil Bio Competitors Puma Biotechnology Competitors Vaxart Competitors Enanta Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BIVI) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredSix Stocks That Could Soar on Trump’s First Day BackThe recent election results have clarified a path forward, creating opportunities that weren't as clear just m...InvestorPlace | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | Sponsored"This looks and feels like 2000," says investing legendOur senior analyst Dan Ferris says a new surprise crisis could begin at any moment... and this time, he says i...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
